1 / 10

Breaking Down Practices v1.0: Applications

This document explores the real challenges posed by synthetic biology (syn bio) in comparison to traditional genetic engineering approaches. It highlights the importance of abstraction, standardization, and composability for enabling complex systems engineering. Key topics include assessing low vs. high-risk/benefit technologies, the fragmented regulatory landscape, and examining case studies from SynBERC's testbed portfolio. With insights from experts like Jay Keasling and Adam Arkin, this work provides valuable perspectives on the current reality and future promises of synthetic biology applications.

taylor
Télécharger la présentation

Breaking Down Practices v1.0: Applications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Breaking Down Practices v1.0: Applications Megan Palmer May 10th 2011

  2. PCSBI FAQs

  3. What are new, real challenges that SB poses in this domain? • Justifying / distinguishing syn bio vs trad genetic eng approaches • Abstraction, standardization, composability enabling complex systems engineering • Difference in process vs kind (e.g. fast, cheap, safe vs altogether different) • Taking advantage of biology’s toolkit (reproduction, evolution, interaction) • Success often evaluated largely by applications, whereas greatest benefit may be cross-cutting technology platforms (i.e. tools) • e.g. (SynB)ERC top-down model in which testbeds drive technology • Merits of high vs low risk / benefit technologies (Lim e.g. ‘toys’)? • Articulating present reality, future promises and intermediate successes

  4. How might this relate to your current or future work? • (Re-)inventing the wheel (we’re different yet the same) • Fragmented regulatory landscape; largely application-dependent

  5. What case studies might be relevant? • SynBERC’s testbed portfolio - rationale (or lack thereof) as motivating for technology platform development • Retired Testbeds: TDB • Current Testbeds: MCF, ‘Industrial’ • Future Testbeds: Cyanobacteria, Stem Cells • ‘Syn bio’-labeled commercial applications • e.g. biofuels. artemisinin

  6. Who are people that might help us work through these problems? • Jay Keasling - SynBERC’s model • Adam Arkin - Recent white paper on ‘the new bioeconomy’ • Harvey Blanch (CSTO @ JBEI) - BioEconomics • Tom Kalil @ OSTP - Roadmap for Fed Investment in Biotech

  7. Can you find articles (or other resources) we might draw upon for background? • Innumerable Reviews Touching on ‘Application Landscapes’ and Roadmaps • Synthetic Society Meeting Notes • Arkin White Paper on ‘The New Bioeconomy’

  8. Akin A. 2008.Setting the standard in synthetic biology. Nature Biotechnology. • Such community repositories will yield the most benefit when synthetic-biology designs scale to systems requiring many interacting parts, thereby limiting the utility of even inspired tinkering to optimize function….Although we cannot quite yet imagine what synthetic biological applications might requirethe numbers and quality of elements on which these advanced technological systems rely, it is economically and socially important that we improve the efficiency, reliability and predictability of our biological designs.

  9. Notes fr. Discussions with Adam Arkin penicillin Programs syn bio route? metabolic eng Pipes rational protein eng Discovery Design

More Related